|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CGA |
Gene summary for CGA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CGA | Gene ID | 1081 |
| Gene name | glycoprotein hormones, alpha polypeptide | |
| Gene Alias | CG-ALPHA | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01215 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1081 | CGA | GSM4909307 | Human | Breast | IDC | 1.11e-28 | 6.67e-01 | 0.1569 |
| 1081 | CGA | GSM4909308 | Human | Breast | IDC | 1.19e-15 | 3.73e-01 | 0.158 |
| 1081 | CGA | GSM4909319 | Human | Breast | IDC | 1.48e-02 | 2.39e-01 | 0.1563 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:003250614 | Esophagus | ESCC | cytokinetic process | 35/8552 | 39/18723 | 9.38e-09 | 1.90e-07 | 35 |
| GO:009030715 | Esophagus | ESCC | mitotic spindle assembly | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:00086081 | Esophagus | ESCC | attachment of spindle microtubules to kinetochore | 29/8552 | 35/18723 | 6.61e-06 | 6.75e-05 | 29 |
| GO:003086517 | Esophagus | ESCC | cortical cytoskeleton organization | 44/8552 | 61/18723 | 2.50e-05 | 2.13e-04 | 44 |
| GO:00519882 | Esophagus | ESCC | regulation of attachment of spindle microtubules to kinetochore | 13/8552 | 13/18723 | 3.75e-05 | 3.04e-04 | 13 |
| GO:00324653 | Esophagus | ESCC | regulation of cytokinesis | 57/8552 | 92/18723 | 1.20e-03 | 5.88e-03 | 57 |
| GO:003086610 | Esophagus | ESCC | cortical actin cytoskeleton organization | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
| GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
| GO:00513025 | Esophagus | ESCC | regulation of cell division | 97/8552 | 177/18723 | 8.93e-03 | 3.12e-02 | 97 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CGA | SNV | Missense_Mutation | c.30N>G | p.Ile10Met | p.I10M | protein_coding | deleterious_low_confidence(0.02) | benign(0.295) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | novel | c.232N>A | p.Ala78Thr | p.A78T | protein_coding | tolerated(0.53) | benign(0.121) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.433C>G | p.His145Asp | p.H145D | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
| CGA | SNV | Missense_Mutation | rs145503313 | c.322N>A | p.Val108Ile | p.V108I | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CGA | SNV | Missense_Mutation | novel | c.373N>A | p.Val125Ile | p.V125I | protein_coding | tolerated(0.52) | benign(0.073) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.185N>A | p.Cys62Tyr | p.C62Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | c.317N>C | p.Lys106Thr | p.K106T | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | novel | c.4N>A | p.Asp2Asn | p.D2N | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.856) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.297N>T | p.Lys99Asn | p.K99N | protein_coding | deleterious(0.05) | possibly_damaging(0.51) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | rs745838602 | c.407N>T | p.Ala136Val | p.A136V | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | VINBLASTINE | VINBLASTINE | 6181870 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 4-{([(4'-CHLOROPHENYL)AMINO]CARBONYLAMINO)}BENZENESULFONAMIDE | CHEMBL1446150 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CIS-DIAMMINEDICHLOROPLATINUM | 6181870 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TUMOR NECROSIS FACTOR | 9764349,10788437 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | IL-18 | 11712764 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 9-CIS-RETINOIC ACID | 8070357 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TESTOSTERONE | TESTOSTERONE | 1157041 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CORTICOSTEROIDS | 3106008 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |